Aktienanalyse zu Johnson & Johnson (JNJ)JNJJohnson & Johnson

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. Its segments include Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include CARVYKTI (ciltacabtagene autoleucel), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), ERLEADA (apalutamide), among others. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a range of acute and elective procedures. The Cardiovascular portfolio includes electrophysiology products. It is also focused on proprietary Firelink degrader antibody conjugate platform. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Johnson & Johnson is not a strong buy due to its recent price decline of 2.25% over the last five days and an RSI of 46.148, indicating a neutral momentum. However, its strong revenue growth of 6% year-over-year and a forward P/E ratio of 21.0084 suggest potential for long-term appreciation. The main risk is the recent insider selling, which has increased by 159.20%, indicating possible lack of confidence from insiders.

23 analysts cover JNJ: 12 rate it Buy, 8 Hold and 3 Sell. The average price target is 218.50.